pathology of nafld - · pdf filepathology of nafld pierre bedossa departement of pathology...

Download PATHOLOGY OF NAFLD -  · PDF filePATHOLOGY OF NAFLD Pierre Bedossa Departement of Pathology Hôpital Beaujon University Paris-Diderot Paris - FRANCE 1 PHC, Paris, 30th Jan 2017

If you can't read please download the document

Upload: dangthuy

Post on 06-Feb-2018

221 views

Category:

Documents


4 download

TRANSCRIPT

  • PATHOLOGY OF NAFLD

    Pierre BedossaDepartement of Pathology

    Hpital BeaujonUniversity Paris-Diderot

    Paris - FRANCE

    1

    PHC, Paris, 30th Jan 2017

  • NAFLD: a chronic liver disease with a wide range of tissue lesions

    Liver biopsy allows an integrated evaluation of tissue damages related to various pathophysiological mechanisms

    Histology is central for disease definitions and prognosis in NAFLD

    Non invasive biomarkers are still unmet need

    2

    PATHOLOGY OF NAFLD

  • CLASSIFICATIONS OF NAFLD :

    INTEGRATED APPROACH (NASH CRN)

    ANALYTICAL APPROACH (SAF)

    HISTOLOGY IN CLINICAL TRIALS

    3

    OUTLINES

  • STEATOSIS(NAFL)

    STEATOHEPATITIS

    (NASH)

    HISTORICAL LANDMARK Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed

    disease. Ludwig J, et al. Mayo Clin Proc. 1980

    THE CLASSICAL VIEW : A DICHOTOMOUS CLASSIFICATION

    Non Alcoholic Fatty Liver Diseases (NAFLD)

  • STEATOHEPATITIS

    (NASH) FIBROSIS

    CIRRHOSIS

    HCC

    STEATOSIS (NAFL)

    THE NATURAL HISTORY OF NAFLD

  • STEATOHEPATITIS

    (NASH) FIBROSIS

    CIRRHOSIS

    HCC

    STEATOSIS (NAFL)

    NASH : ASSOCIATION OF HISTOLOGICAL PATTERNS

    STEATOSIS+

    BALLOONING+

    INFLAMMATION+

    Perisinusoidal fibrosis+

    Location in zone 3

  • STEATOSIS(NAFL)

    STEATOHEPATITIS

    (NASH)

    THE LIMIT OF A DICHOTOMOUS CLASSIFICATION

    BO

    RD

    ERL I

    NE

  • STEATOSIS(NAFL)

    STEATOHEPATITIS

    (NASH)

    THE LIMIT OF A DICHOTOMOUS CLASSIFICATION

    BO

    RD

    ERL I

    NE

  • + BALLONING

    1 2

    + INFLAMMATION

    1 2 3

    NAFLD Activity Score (NAS, 0-8)

    STEATOSIS

    1 2 3

    NASH CRN, Hepatology 2005

  • Correlation between NAS and histologic diagnosis of NASH

    < 3: no NASH 3-4 : GREY ZONE

    >5 : definitively NASH

    NAS = Sum of lesions related to different mechanisms and with different clinical relevance (steatosis vs hepatocellular injury)

    Ballooning (0-2) underweighted vs steatosis (0-3) or inflammation (0-3)

    NAS has not been shown as a prognostic factor

    NAFLD Activity Score (NAS, 0-8)

  • CLASSIFICATIONS OF NAFLD :

    INTEGRATED APPROACH (NASH CRN)

    ANALYTICAL APPROACH (SAF)

    HISTOLOGY IN CLINICAL TRIALS

    11

    OUTLINES

  • 12

    STEATOSIS

    FIBROSIS

    FLIP consortium, Hepatology 2012, Hepatology 2014

    THE MARKER

    ACTIVITYTHE DRIVER

    THE KILLER

    UNDER THE LENS : THE 3 HISTOLOGICAL COMPONENTS OF NAFLD

  • Steatosis (0-3) as for NASH CRN ACTIVITY (0-4) = BALLOONING (0-2) + LOBULAR

    INFLAMMATION (0-2)

    Fibrosis (0 4) as for NASH CRNS0-3A0-4F0-4

    The S.A.F. score(Steatosis-Activity-Fibrosis)

    Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, Tordjman J, Clement K. Hepatology. 2012 Nov;56(5):1751-9

  • 14

    STEATOSISTHE MARKER

  • 15

    Ballooning

    Inflammation

    ACTIVITYTHE DRIVER

  • 16

    HEPATOCELLULAR BALLOONING: THE HALLMARK OF NASH SHAPE + COLOR + SIZE

    Ballooning 1 Ballooning 2

    NORMAL LIVER CK18

  • Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, Tordjman J, Clement K. Hepatology. 2012 Nov;56(5):1751-9

    The FLIP algorithm

    NAFL NAFLNAFL

    NAFLNASHNASHNAFL NASHNASH

  • 40 biopsies (Steatosis, NASH) 1st session(unsupervised)

    2nd session (with classifier)

    Liver Pathologists (n=6) score 0.54 (moderate) 0.66 (substantial) Nbr of biopsies with agreement

    between all pathologists 26/40 (65 %) 34/40 (85 %)

    General Pathologists (n=10) score 0.35 (fair) 0.70 (substantial) Nbr of biopsies with agreement

    between all pathologists 18/40 (45 %) 34/40 (85 %)

    REPRODUCIBILITY OF DIAGNOSIS OF NASH WITH FLIP ALGORITHM

    The definition of NASH by an association of 3 features and a clear definition of each of them make the diagnosis of NASH strongly reproducible

    The FLIP Pathology consortium, Hepatology 2014

  • 19

    FIBROSISTHE KILLER

  • Younossi ZM, Stepanova M, Rafiq N, et al.. Hepatology 2011 Ekstedt M, Hagstrm H, Nasr P et al, Hepatology 2015

    LIVER FIBROSIS : MAJOR PROGNOSTIC FACTOR

    Overal survival according to stage of fibrosis in index biopsy

    Liver Related Mortality

    Overal survival according to fibrosis stage and compared to

    control population

  • Stage of Fibrosis (Kleiner et al, Hepatology 2005) 1

    2 3

    0

    4

  • STAGE OF FIBROSIS: ROOM FOR IMPROVEMENT

  • 23

    STAGE OF FIBROSIS: ROOM FOR IMPROVEMENT

    STAGE 3 / SEPTAL FIBROSIS

  • OUTLINES

    CLASSIFICATION OF NAFLD : INTEGRATED APPROACH ANALYTICAL APPROACH

    HISTOLOGY IN CLINICAL TRIALS Histology is a validated surrogate endpoint

    24

    PATHOLOGY OF NAFLD

  • 25

    ACTIVITY

    FIBR

    OS

    IS

    MANY SHADES OF NAFLD

  • 26

    ACTIVITY

    FIBR

    OS

    IS

    MANY SHADES OF NAFLD

    A0F1

  • 27

    ACTIVITY

    FIBR

    OS

    IS

    MANY SHADES OF NAFLD

  • 28

    ACTIVITY

    FIBR

    OS

    IS

    MANY SHADES OF NAFLD

    A3F1

  • 29

    ACTIVITY

    FIBR

    OS

    IS

    MANY SHADES OF NAFLD

  • 30

    ACTIVITY

    FIBR

    OS

    IS

    MANY SHADES OF NAFLD

    A0F4

  • 31

    ACTIVITY

    FIBR

    OS

    IS

    MANY SHADES OF NAFLD

  • 32

    ACTIVITY

    FIBR

    OS

    IS

    MANY SHADES OF NAFLD

    A3F4

  • 33

    ACTIVITY

    FIBR

    OS

    IS

    MANY SHADES OF NAFLD

    A3F4A0F4

    A3F1A0F1

  • STEATOSIS +

    A0 A1 A2 A3 A4

    F0 A0F0 A1F0 A2F0 A3F0 A4F0

    F1 A0F1 A1F1 A2F1 A3F1 A4F1

    F2 A0F2 A1F2 A2F2 A3F2 A4F2

    F3 A0F3 A1F3 A2F3 A3F3 A4F3

    F4 A0F4 A1F4 A2F4 A3F4 A4F4

    34

    HISTOLOGY IN NAFLD CLINICAL TRIALS

  • STEATOSIS +

    A0 A1 A2 A3 A4

    F0 A0F0 A1F0 A2F0 A3F0 A4F0

    F1 A0F1 A1F1 A2F1 A3F1 A4F1

    F2 A0F2 A1F2 A2F2 A3F2 A4F2

    F3 A0F3 A1F3 A2F3 A3F3 A4F3

    F4 A0F4 A1F4 A2F4 A3F4 A4F4

    35

    HISTOLOGY IN NAFLD CLINICAL TRIALS

  • STEATOSIS +

    A0 A1 A2 A3 A4

    F0 A0F0 A1F0 A2F0 A3F0 A4F0

    F1 A0F1 A1F1 A2F1 A3F1 A4F1

    F2 A0F2 A1F2 A2F2 A3F2 A4F2

    F3 A0F3 A1F3 A2F3 A3F3 A4F3

    F4 A0F4 A1F4 A2F4 A3F4 A4F4

    36

    HISTOLOGY IN NAFLD CLINICAL TRIALS

  • STEATOSIS +

    A0 A1 A2 A3 A4

    F0 A0F0 A1F0 A2F0 A3F0 A4F0

    F1 A0F1 A1F1 A2F1 A3F1 A4F1

    F2 A0F2 A1F2 A2F2 A3F2 A4F2

    F3 A0F3 A1F3 A2F3 A3F3 A4F3

    F4 A0F4 A1F4 A2F4 A3F4 A4F4

    37

    HISTOLOGY IN NAFLD CLINICAL TRIALS

  • STEATOSIS +

    A0 A1 A2 A3 A4

    F0 A0F0 A1F0 A2F0 A3F0 A4F0

    F1 A0F1 A1F1 A2F1 A3F1 A4F1

    F2 A0F2 A1F2 A2F2 A3F2 A4F2

    F3 A0F3 A1F3 A2F3 A3F3 A4F3

    F4 A0F4 A1F4 A2F4 A3F4 A4F4

    38

    RESOLUTION OF NASH WITHOUT WORSENING OF FIBROSIS

    RE

    GR

    ES

    SIO

    N O

    F FIBR

    OS

    IS W

    ITHO

    UT

    WO

    RS

    EN

    ING

    OF N

    AS

    H

    CURING THE DISEASE

    ENDPOINT IN CLINICAL TRIALS

  • PATHOLOGY OF NAFLD Take-home messages

    NAFLD is the combination of several features of variable intensity and of different prognostic values.

    The dichotomous classification NAFL vs NASH is an oversimplification which is no more relevant in clinical practice. New proposals have been formulated.

    NASH is defined by histological criteria. Therefore, biopsy is needed if diagnosis and evaluation of severity are required.

    Histology is the only accepted surrogate marker in clinical trials

    Non invasive markers are urgently needed

  • THANK YOU FOR YOUR ATTENTION !

    40

    Slide 1Slide 2Slide 3Slide 4Slide 5Slide 6Slide 7Slide 8NAFLD Activity Score (NAS, 0-8)NAFLD Activity Score (NAS, 0-8)Slide 11Slide 12The S.A.F. score (Steatosis-Activity-Fibrosis)Slide 14Slide 15Slide 16Slide 17REPRODUCIBILITY OF DIAGNOSIS OF NASH WITH FLIP ALGORITHMSlide 19LIVER FIBROSIS : MAJOR PROGNOSTIC FACTORSlide 21Slide 22Slide 23OUTLINESSlide 25Slide 26Slide 27Slide 28Slide 29Slide 30Slide 31Slide 32Slide 33Slide 34Slide 35Slide 36Slide 37Slide 38PATHOLOGY OF NAFLD Take-home messagesSlide 40